Autolus Therapeutics (AUTL) Share-based Compensation (2018 - 2025)
Autolus Therapeutics' (AUTL) quarterly Share-based Compensation came in at $3.4 million in Q4 2025, down 44.76% YoY from $6.2 million in Q4 2024, and down 10.22% on a QoQ basis from $3.8 million in Q3 2025.
Autolus Therapeutics (AUTL) Share-based Compensation (2018 - 2025) Analysis & Trends
Autolus Therapeutics (AUTL) has 8 years of Share-based Compensation data on file, last reported at $3.4 million in Q4 2025.
- Quarterly Share-based Compensation fell 44.76% year-over-year to $3.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.4 million (down 6.68% YoY) and the FY2025 annual result came in at $14.4 million, down 6.68% from the prior year.
- Share-based Compensation eased to $3.4 million in Q4 2025, from $3.8 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $27.9 million in Q3 2021 to a low of -$18.6 million in Q4 2021.
- A 5-year average of $4.7 million and a median of $3.4 million in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2021 — Share-based Compensation plunged 267.64% — and 2024, when it surged 9993.65%.
- Tracing AUTL's Share-based Compensation over 5 years: stood at -$18.6 million in 2021, then soared by 118.38% to $3.4 million in 2022, then plunged by 101.84% to -$63000.0 in 2023, then surged by 9993.65% to $6.2 million in 2024, then sank by 44.76% to $3.4 million in 2025.
- The last three Share-based Compensation figures came in at $3.4 million (Q4 2025), $3.8 million (Q3 2025), and $4.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Autolus Therapeutics | 763.37 Mn | 561.74 Mn | 25.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.44 Mn |
| Dec 31, 2025 | 3.44 Mn |
| Sep 30, 2025 | 3.84 Mn |
| Sep 30, 2025 | 3.84 Mn |
| Jun 30, 2025 | 4.29 Mn |
| Jun 30, 2025 | 4.29 Mn |
| Mar 31, 2025 | 2.87 Mn |
| Mar 31, 2025 | 2.87 Mn |
| Dec 31, 2024 | 6.23 Mn |
| Dec 31, 2024 | 6.23 Mn |
| Sep 30, 2024 | 4.02 Mn |
| Sep 30, 2024 | 4.02 Mn |
| Jun 30, 2024 | 2.94 Mn |
| Jun 30, 2024 | 2.94 Mn |
| Mar 31, 2024 | 2.28 Mn |
| Mar 31, 2024 | 2.28 Mn |
| Dec 31, 2023 | -63,000.00 |
| Dec 31, 2023 | -63,000.00 |
| Sep 30, 2023 | 8.31 Mn |
| Sep 30, 2023 | 8.31 Mn |